Law Firm Investigation Adds Legal Overhang to AVAV's SCAR Program Risk

What happened

Berger Montague PC announced an investigation into AeroVironment's board for potential breach of fiduciary duty, focusing on whether the company concealed its exposure to competition for the U.S. Space Force's SCAR program. This follows earlier disclosures that the SCAR BADGER program was stopped and terminated, leading to a ~$240.7 million goodwill impairment and the removal of $1.49 billion in unexercised SCAR options from backlog. The investigation suggests the board may have known about competitive threats to the SCAR award before public disclosure, potentially inflating the stock price. The DeepValue master report already rates AVAV a WAIT due to execution risks, margin pressure, and internal control weaknesses, and this legal overhang adds another layer of uncertainty. Investors should note that a law firm investigation is not a formal finding of wrongdoing, but it can lead to securities litigation and distraction for management.

Implication

The investigation is focused on whether the board concealed material information about SCAR competition, which could expose the company to shareholder lawsuits and potential damages if allegations are proven. For investors, this increases the risk that previously reported financials and disclosures related to SCAR may need to be revisited, possibly leading to further restatements or control findings. However, the core growth thesis for AVAV in counter-UAS and loitering munitions remains intact, as the SCAR program was already known to be impaired and removed from backlog. The stock already trades at a discount due to control weaknesses and margin concerns, and this news may delay any re-rating until the legal situation clarifies. Investors should monitor for additional law firm announcements, class action filings, or management responses, and should continue to demand evidence of backlog conversion and control remediation before adding positions.

Thesis delta

The investigation introduces a new governance risk that was not previously priced into the WAIT thesis. While the underlying demand fundamentals are unchanged, the potential for concealed SCAR competition exposure adds litigation uncertainty and further delays conviction in management's credibility. This shifts the risk-reward further against near-term buying, reinforcing the WAIT rating with a lower conviction until more details emerge.